Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics

Sanoh, S. Ohta, S.
Biopharm Drug Dispos. 2014 Mar;35(2):71-86.

Chimeric Mice with Humanized Livers: A Unique Tool for in Vivo and in Vitro Enzyme Induction Studies

Masakazu Kakuni, Chihiro Yamasaki, Asato Tachibana, Yasumi Yoshizane, Yuji Ishida and Chise Tateno
Int. J. Mol. Sci. 2014, 15, 58-74

Hepatitis Virus Infection Affects DNA Methylation in Mice with Humanized Livers

Okamoto, Y. Shinjo, K., Shimizu, Y. Sano, T. Yamao, K. Gao, W. Fujii, M. Osada, H. Sekido, Y. Murakami, S. Tanaka, Y. Joh, T. Sato, S. Takahashi, S. Wakita, T. Zhu, J.Issa, J. P. Kondo, Y.
Gastroenterology. 2014 Feb;146(2):562-72.

Long-Term Elimination of Hepatitis C Virus from Human Hepatocyte Chimeric Mice After Interferon-gamma Gene Transfer

Takahashi, Y. Ando, M. Nishikawa, M. Hiraga, N. Imamura, M. Chayama, K. Takakura, Y.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):28-39.

Formulated Minimal-Length Synthetic Small Hairpin RNAs are Potent Inhibitors of Hepatitis C Virus in Mice with Humanized Livers

Ma, H. Dallas, A. Ilves, H. Shorenstein, J. Maclachlan, I. Klumpp, K. Johnston, B. H.
Gastroenterology. 2014 Jan;146(1):63-6.

In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver

Igawa, Y. Fujitani, T. Shah, B. Oo, C. Kanai, Y.
Xenobiotica. 2014 Jan;44(2):154-63.

Endogenous and xenobiotic metabolite profiling of liver extracts from SCID and chimeric humanized mice following repeated oral administration of troglitazone

Barnes, A. J. Baker, D. R. Hobby, K. Ashton, S. Michopoulos, F. Spagou, K. Loftus, N. J. Wilson, I. D.
Xenobiotica. 2014 Jan; 44(2): 174-85.

Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver

Kitamura, S. Sugihara, K.
Xenobiotica. 2014 Jan; 44(2): 123-34.

Isolation and characterization of highly replicable hepatitis C virus genotype 1a strain

Arai M, Tokunaga Y, Takagi A, Tobita Y, Hirata Y, Ishida Y, TatenoC, Kohara M
PLoS One. 2013 Dec 16;8(12):e82527.

HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-beta type I receptor

Sakata, K. Hara, M. Terada, T. Watanabe, N. Takaya, D. Yaguchi, S. Matsumoto, T. Matsuura, T. Shirouzu, M. Yokoyama, S. Yamaguchi, T. Miyazawa, K. Aizaki, H. Suzuki, T. Wakita, T. Imoto, M. Kojima, S.
Sci Rep. 2013 Nov 22;3:3243. doi: 10.1038/srep03243.

Transplantation of engineered chimeric liver with autologous hepatocytes and xenobiotic scaffold

Hata T, Uemoto S, Fujimoto Y, Murakami T, Tateno C, Yoshizato K, Kobayashi E.
Ann Surg. 2013 Mar;257(3):542-7.

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.

Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M.
Gut. 2013 Sep;62(9):1340-6

Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection.

Nakagawa S, Hirata Y, Kameyama T, Tokunaga Y, Nishito Y, Hirabayashi K, Yano J, Ochiya T, Tateno C, Tanaka Y, Mizokami M, Tsukiyama-Kohara K, Inoue K, Yoshiba M, Takaoka A, Kohara M.
PLoS One. 2013;8(3):e59611.

Thromboxane A2 Synthase Inhibitors Prevent Production of Infectious Hepatitis C Virus in Mice with Humanized Livers.

Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, Chayama K, Hijikata M
Gastroenterology. 2013 Sep;145(3):658-67.e11.

A Serine Palmitoyltransferase Inhibitor Inhibits Hepatitis C Virus Replication in Human Hepatocytes.

Katsume A, Tokunaga Y, Hirata Y, Munakata T, Saito M, Hayashi H, Okamoto K, Ohmori Y, Kusanagi I, Fujiwara S, Tsukuda T, Aoki Y, Klumpp K, Tsukiyama-Kohara K, El-Gohary A, Sudoh M, Kohara M.
Gastroenterology. 2013 Oct;145(4):865-73.

Demonstration of hepatitis C virus RNA with in situ hybridization employing a locked nucleic Acid probe in humanized liver of infected chimeric mice and in needle-biopsied human liver.

Shiogama K, Inada K, Kohara M, Teramoto H, Mizutani Y, Onouchi T, Tsutsumi Y.
Int J Hepatol. 2013;2013:249535. doi: 10.1155/2013/249535. Epub 2013 Jun 18.

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.

Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K.
Gut. 2013 Jul;62(7):1055-61

A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next?

Yoshizato, K. Tateno, C.

Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1419-35.

Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice

Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T
Gastroenterology. 2013 Aug;145(2): 447-455.

Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes.

Tanoue C, Sugihara K, Uramaru N, Tayama Y, Watanabe Y, Horie T, Ohta S, Kitamura S
Xenobiotica. 2013 Nov;43(11):956-62.